PharmaMar Announces The Initiation Of Phase II Studies With Irvalec®

PharmaMar, a biotechnology company from Zeltia Group, announces the initiation of a Phase II multicenter study of Irvalec® in patients with non- microcitic lung cancer. The study will test the therapy in patients who have undergone platinum based chemotherapy. Lung cancer is the main cause of death by cancer. There are different types of the disease.

More: continued here

Filed under: Clinical Trials on January 4th, 2009